Diphenhydramine hydrochloride
Drug30 mL at bedtime
Other names: Zzzquil
NCT Number: NCT02578186
The present study was conducted to investigate the impact of diphenhydramine hydrochloride on the ability to initiate sleep.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 4
Diphenhydramine hydrochloride (herein referred to as diphenhydramine) is an antihistamine of the ethanolamine classes with known sleep-inducing properties and is approved by the Food & Drug Administration to reduce the time to sleep onset in individuals having difficulty falling asleep. The goal of the study is to investigate diphenhydramine versus placebo with regard to several sleep parameters, including time to sleep onset, in healthy adult subjects suffering from occasional sleeplessness.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
30 mL at bedtime
Other names: Zzzquil
30 mL at bedtime
Other names: placebo comparator
Time frame: 4 weeks
Per Protocol population based on subjects who completed treatment crossover
Procter and Gamble
Industry
Randomized, Double-Blind, Placebo-Controlled, Crossover, In-home Study to Assess the Efficacy of Diphenhydramine Hydrochloride in Subjects With Occasional Sleeplessness
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.